PD-L1 Blocking CAR-T Vector for Immune Escape Suppression

The patent creates a functional copy of the monoclonal antibody's blocking capability by expressing a humanized anti-PD-L1 scFv gene in T cells. This genetic copy enables the T cells to produce the blocking protein internally, eliminating the need for repeated expensive commercial antibody administrations while maintaining the same therapeutic effect of suppressing immune escape.

The patent enables T cells to self-produce the PD-L1 blocking protein through genetic modification. The modified T cells autonomously express the anti-PD-L1 scFv and secrete it to block PD-L1 on tumor cells, making the system self-sufficient and eliminating ongoing dependence on external expensive antibody treatments.

The patent merges the CAR targeting function with the PD-L1 blocking function into a single genetically modified T cell. The T cell simultaneously expresses both the CAR receptor for target recognition and the anti-PD-L1 scFv for immune escape suppression, ensuring that the blocking function is delivered precisely to target cells through the CAR-mediated targeting mechanism.

The patent uses the CAR-T cell itself as an intermediary vehicle to deliver the PD-L1 blocking function. Instead of administering free-floating antibodies that have low delivery efficiency, the modified T cell acts as a living carrier that actively seeks out and delivers the blocking function directly to PD-L1 expressing tumor cells through its CAR-mediated targeting capability.